Monday, 30 January 2012

Myeloid Nuclear Differentiation Antigen

This anti-MNDA reagent is suitable for flow cytometry to diagnose myelodysplastic syndromes ("preleukemia").

Flow Cytometric Assessment of Myeloid Nuclear Differentiation Antigen (MNDA) Expression in the diagnosis of Myelodysplastic Syndromes

Unique features - MNDA

  • Unique product (Rat anti Human antibody
  • Anti-MNDA for using in the flow cytometry
  • Blood and bone marrow staining using flow cytometry (down-regulation of MNDA in cases of MDS)
  • Unique  intracellular staining  procedure using  Intra-Cell™   (Trillium DiagnosticsLLC, USA), also distributed by IQ Products
The myelodysplastic syndromes (MDS), formerly known as ‘preleukemia’, are a diverse collection of hematological (blood-related) medical conditions that involve ineffective production (or dysplasia) of the myeloid class of blood cells. Patients with MDS often develop severe anemia and require frequent blood transfusions. In most cases, the disease worsens and the patient develops low blood counts (cytopenias) due to progressive bone marrow failure. In about one third of patients with MDS the disease transforms into AML, usually within months to a few years. The MDS are all disorders of the stem cell in the bone marrow.

Definitive diagnosis and classification of Myelodysplastic Syndrome (MDS) are often difficult because of variable presence of diagnostic criteria. An objective criterion that reliably distinguishes MDS from normal marrow would greatly facilitate diagnosis, and might contribute to sub classification of MDS.

Gene expression profiling has identified marked down-regulation of MNDA message in cases of MDS (1). Previously there is shown down-regulation of MNDA protein expression in random MDS cases using immunohistochemistry and flow cytometry (2).


Blood or bone marrow staining method for anti-MNDA using Trillium Intra-Cell™ intracellular staining method. This method contains a fixation step with 10% formaldehyde, permeabilization step with Trillium Intra-Cell™ and a staining step with anti-MNDA FITC and a desired surface markers such as CD163 PE and CD45 PerCP.

MDNA - Pure - MNDA-3C1-U

Rat anti human MNDA (clone 3C1), available pure and FITC conjugated. Which was generated against aconcentrated nuclear protein extract prepared from late stage human myeloid leukaemia HL-60 cells.

No comments:

Post a Comment

Webmaster: AnnWebCom | Site design: Creative Copyright 2005-2015 Caltag-Medsystems Limited - all rights reserved